In a different mouse colon carcinoma tumor model, CT26, significant tumor growth inhibition was also observed upon anti-PD-L1 (atezolizumab, which cross reacts with murine PD-L1) plus anti-TGF-β treatment, whether anti-TGF-β was given intraperitoneally (I.P.)or intratumorally (I.T.)(Additional file 1, Figure S2). The gene discussed is TGFB1; the disease is neoplasm.